Experience with Lamivudine against Hepatitis B Virus

Intervirology

Volumn 40, Issue 5-6, 1997, Pages 322-336

  Jaeckel, Elmar ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic hepatitis; Combination therapy; Cross resistance; Famciclovir; Ganciclovir; Hepatitis B virus; Human immunodeficiency virus; Immunosuppression; Interferon; Lamivudine; Molecular actions; Nucleoside metabolism; Orthotopic liver transplantation; Resistance

Indexed keywords

LAMIVUDINE; NUCLEOSIDE ANALOG;

ARTHRALGIA; ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG METABOLISM; FATIGUE; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MYOPATHY; NAUSEA; NEUROPATHY; PARESTHESIA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REINFECTION; SINGLE BLIND PROCEDURE; THROMBOCYTHEMIA; TREMOR; VERTIGO; WEIGHT REDUCTION;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERONS; LAMIVUDINE; LIVER TRANSPLANTATION; MUTATION; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 2642639623     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000150565     Document Type: Article

References (117)

1. Margolis HS, Alter MJ, Hadler SC, Hepatitis B: Evolving epidemiology and implications for control, Semin Liver Dis 1991; 11:84-92.
2. De Jong FE, Janssen HL, de Man RA, Hop WC, Schalm SW, Blankcnstein M: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver, Gastroenterology 1992;103:1630-1635.
3. Beasley RP, Wong LC, Lin CC, Chien CS: Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22.707 men in Taiwan, Lancet 1981;2:1129-1133.
4. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Dctsky AS, Heathcote J: Effect of alpha-interferon treatment in patients with hepatitis B antigen positive chronic hepatitis B, A metaanalysis, Ann Intern Med 1993:1 19:312-323.
5. Niederau C, Heintgcs T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D: Long term follow-up of HBeAg-positive patients treated w ith interferon alfa for chronic hepatitis B, N Engl J Med 1996;334:1422-1427.
6. Macilwain C: N1H, FDA seek lessons from hepatitis B drug trial deaths, Nature 1993:264: 275.
7. Manvick C: NIH panel of'no flaws' in FIAU trial at variance with FDA report: A new probe planned, JAMA 1994;272:9-11.
8. Fried MW, DiBisccglic AM, Strauss SE: Fi, AU, a new oral anti-viral agent profoundly inhibits HBV DNA in patients with chronic hepatitis B, Hepatology 1992; 16:127A.
9. Hoofnagle JH, DiBisccglic AM: Antiviral therapy of viral hepatitis; in Galasso GJ, Whitley RJ, Merigan TC (eds): Antiviral Agents and Viral Diseases of Man, cd 3. New York, Raven Press, 1991. pp 415-459.
10. Luscombe CA, Locarnini SA: The mechanism of action of antiviral agents in chronic hepatitis B, J Viral Hepatitis 1996;2:1-35.
11. Bock OT, Schranz P, Schroder CH, Zentgraf H: Hepatitis B virus genome is organised into nucleosomes in the nucleus of the infected cell, Virus Genes 1994:8:215-229.
12. Newbold JE, Xin H, Tcncza M, Sherman G, Dean J, Bowden DS, Locamini S: The covalently closed duplex form of the hepadnaviral genome exists in situ as a heterogenous population of viral minichromosomes, J Virol 1995: 69:3350-3357.
13. Schallcr H, Fischer M: Transcriptional control of hepadnavirusgene expression, Curr Top Microbiol Immunol 1991;168:21-39.
14. Wang GH, Secger C: The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis, Cell 1992:71:663-670.
15. Tultleman JS, Pourcel C, Summers J: Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells, Cell 1986:47:451-460.
16. Shaw T, Locamini SA: Hepatic purine and pyrimidine metabolism: Implications for antiviral chemotherapy of viral hepatitis, Liver 1995:15:169-184.
17. Soudeycns H, Yao XL Gao Q, Belleau B, Kraus JL, Nguyen-Ba N, Spira B, Wainberg MA: Anti-immunodeficiency vims type I activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analogue, Anlimicrob Agents Chemother 1991; 35:1386-1390.
18. Doong SL, Tsai CH, Schinazi RF, Liolta DC, Cheng YC: Inhibition of the replication of hepatitis B vims in vitro by 2',3'-didcoxy-3'-thiacy-tidine and related analogues, Proc Natl Acad Sci USA 1991,88:8495-8499.
19. Severini A, Liu XY, Wilson JS, Tvrell DU: Mechanism of inhibition of duck hepatitis B vims in vitro by 2',3'-dideoxy-3'-thiacytidine, Antinticrob Agents Chemother 1995:39:1430-1435.
20. Tyrell DU, Fischer K, Cameron J: 2\3'-di-deoxy-3'-thiacytidine treatment of chimpanzees chronically infected with hepatitis B virus results in rapid suppression of HBV DNA in serum, Programme and abstracts of the 18th International Symposium on Viral Hepatitis and Liver Disease, Tokyo, Viral Hepatitis Foundation Japan, 1993. p 156.
21. Tyrell DU, Fischer K, Savani K, Tan W, Jewell L: Treatment of chimpanzees and ducks with lamivudine results in a rapid suppression of hepadnaviral DNA in sera, Clin Invest Med 1993:16(suppl 4):B77.
22. Shewatch DS, Liotta DC, Schinazi RF: Nucleotide specificity of human deoxycvtidine kinase, Mol Pharmacol 1992:42:518-524.
23. Chang CN, Doong SL, Zhou HJ, Beach JW, Jeong LS, Chu CK, Tsai CH, Cheng YC, Liotta D, Schinazi R: Deoxycvtidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-didcoxy-3'-lhiacytidine in the inhibition of hepatitis B virus replication, J Biol Chcrn 1992;267:13938-13942.
24. Gerelsaikhan T, Tavis JE, Bruss V: Hepatitis B vims nucleocapsid envelopment docs not occur without genomic DNA synthesis, J Virol 1996; 70:4269-4274.
25. Davis MG, Wilson JE, VanDraanen NA, Miller WH, Frcemann GA, Daluge SM, Boyd FL, Aulabaugh AE, Painter GR, Boone LR: DNA polymerase activity of hepatitis B virus particles: Differential inhibition by /,-enantiomcrs of nucleotide analogues, Antiviral Res 1996:30: 133-145.
26. Chang CN, Skalski V, Zhou JH, Cheng YC: Biochemical pharmacology of (+) and <-)-2',3'-dideoxv-3-thiacytidinc as antihepatitis B virus agents, J BiolChcm 1992:267:22414-22420.
27. Lai CL, Ching CK, Tung AKM, Li E, Young J, Hill A, Wong BCY, Dent J, Wu PC: Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo controlled trial, Hcpatology 1997:25:241-244.
28. Dienstag JL, Pcrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection, N Engl J Med 1995:333:1657-1661.
29. Dienstag JL, Schiff ER, Mitchell M, Gitlin N, Lissoos T, Condrcay L, Garrett L, Rubin M, Brown N: Extended lamivudine retreatment for chronic hepatitis B, Hcpatology 1996:24: 188A.
30. Nevens F, Tyrell DL, De Man RA, Main J, Ber-anek P, Sidar S, Fevcry J, Schalm SW, Thomas HC: A six month dose ranging study of the safety and efficacy of lamivudine in chronic hepatitis B, J Hepatol 1995;23:81-91.
31. Honkoop P, Niesters HG, De Man RA, Oster-haus AD, Schalm SW: Lamivudine resistance in immunocompetent chronic hepatitis B, J Hepatol 1997;26:1393-1395.
32. Van Thiel DH, Fricdlandcr L, Kania RJ, Mol-loy PJ, Hassancin T, Waahlstrom E, Faruki H: Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B, Hepatogastrocnterology 1997:44:808-812.
33. Tyrell DU, Mitchcl MC, De Man RA: Phase II trial of lamivudine for chronic hepatitis B, Hepatology 1993:18:112A.
34. De Man RA, Schalm SW, Main J, Thomas HC, Fcvery J, Nevens F, Staley H: A dose ranging study to determine the antiviral activity and safety of lamivudine in patients with chronic hepatitis B infection, Gut 1993:34:85.
35. Pcrrillo RP: Factors influencing response to interferon in hepatitis B, Implications for Asian and Western populations, Hepatology 1990:12:1433-1434.
36. Maynard JE, Kare MA, Alter MJ, Hadler SC: Control of hepatitis B by immunization: Global perspective: in Zuckerman AJ (ed): Viral Hepatitis and Liver Disease, New York, Liss, 1988. pp 967-969.
37. Hoofnagle JH, Dusheiko GM, Scef LB, Jones EA, Waggoner JG, Bales ZB: Seroconversion from hepatitis Be antigen to antibody in chronic type B hepatitis, Ann Intern Med 1981: 94:744-748.
38. Pcrrillo RP, Schiff ER, Davis GL, Bodenhei-mer HC Jr, Lindsay K, Payne J, Dienstag JL, O'Brien C, Tamburro C, Jacobson IM: A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B, N Engl J Med 1990:323:295-301.
39. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Ruslgi V, Di Bisccglie A, Hallahan C, Park Y, Mcschiewitz C, Jones EA: Randomized, controlled trial of recombinant human a-inter-feron in patients with chronic hepatitis B, Gastroenterology 1988:95:1318-1325.
40. Honkoop P, De Man RA, Zondervan PE, Schalm SW: Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine, Liver 1997; 17:103-106.
41. Lai CL, Liaw YF, Leung N, Chang IT, Guan R, Tai DL Ng KY, Wu PC, Dent J, Gray DF: A 12 month course of lamivudine (100mg qd) therapy improves liver histology: Results of a placebo controlled multicentre study in Asia, J Hepatol 1997;26(suppl 1):79.
42. Perrillo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, Dienstag J, Gish R, Villcneuvc J, Caldwell S, Brown N, Self P: Lamivudine transplant study group, Lamivudine for hepatitis B after liver transplantation (OLT), Hepatology 1996:24:182A.
43. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rollcs K, McMaslcr P, Beranck P, Kennedy F, Kibbler H, McPhillips P, Elias E, Dusheiko G: Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis, Lancet 1996:348:1212-1215.
44. Hart GJ, Orr DC, Penn CR, Figucredo HT, Gray NM, Bochrne RE, Cameron JM: Effects of (-F2',3'-dideoxv-3'-thiacytidine-5' triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerase alpha, beta and gamma, Antimicrobial Agenis Chemother 1992:36:1688-1694.
45. Honkoop P, De Man RA, Schole HR, Zondervan PE, Van den Berg JWO, Rademakers HPM, Schalm SW: Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B, Hepatology 1997:26:211-215.
46. Honkoop P, De Man RA, Heijtink RA, Schalm SW: Hepatitis B reactivation alter lamivudine, Lancet 1995:346:1156-1157.
47. Dean J, Bowden S, Locamini S: Reversion of duck hepatitis B virus DNA replication following cessation of treatment with the nucleoside analogue ganciclovir, Antiviral Res 1995:27: 171-178.
48. Civit co G, Locamini S: The half life of duck hepatitis B virus supercoiled DNA in congenitally nfected primary hepatocvte cultures, Virology 1994:203:81-89.
49. Blum HE, Stowring L, Figus A, Montgomery' CK, Haase AT, Vyas GN: Detection of hepatitis B virus DNA in hepatocytcs, bile duct epithelium and vascular elements by in situ hy-bridsation, Proc Nall Acad Sci USA 1983:80: 6685-6688.
50. Dclladctsima JK, Vafiadsi I, Tassopoulas NC, Kyriakou V, Apostolaki A, SmymoffT: HBcAg and HBcAg expression in ductular cells in chronic hepatitis B, Liver 1994:14:71-75.
51. Luscombe C, Pedersen J, Uren E, Locarnini S: Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: Effect on intrahepatic viral DNA, RNA and protein expression, Hepatology 1996:24:766-773.
52. Colledge D, Locarnini S, Shaw T: Synergistic inhibition of hepadnaviral replication by lami-vudinc in combination with penciclovir in vitro, Hepatology 1997:26:216-225.
53. Nowak MA, Bonhoeffer S, Hill AM, Bochmc R, Thomas HC, McDade H: Viral dynamics in hepatitis B infection, Proc Natl Acad Sci USA 1996;93:4398-4402.
54. De Man RA, Niestcrs HGM, Fevery J, Main J, Nevens F, Schalm SW, Thomas HC, Tyrell DL: Evaluation by limiting dilution PCR of HBV-DNA decrease in a double blind randomised six month trial of lamivudine for chronic hepatitis B: Implications for the application in liver transplant recipients, J Hepatol 1995;23(suppl 1):96.
55. Bianchi L, Gudat F: in Bianchi L, Gerok W, Sickinger K (eds): Virus and the Liver, Lancaster, MTP, 1980. pp 197-204.
56. Bertoletti A, Sette A, Chisari FV, Penna A, Lcvrcro M, Decarli M, Fiaccadori F, Ferrari C: Natural variants of cytotoxic epitopes arc T-cell receptor antagonists for antiviral cytotoxic T-cells, Nature 1994;369:407-410.
57. Mason WS, Cullen J, Saputelli J, Wu TT, Liu C, London WT, Lustbader E, Schaffer P, O'Conell AP, Fourel 1. Aldrich CE, Jilbert AR: Characterization of the antiviral effects of 2'-carbodeoxvguanosine in ducks chronically infected with duck hepatitis B virus, Hepatology 1994:19:398-411.
58. Corey L, Holmes KK: Therapy for human immunodeficiency virus infection - What have we learned? N Engl J Med 1996:335:1142-1144.
59. Trcpo C, Jezek P, Atkinson GF, Boon RJ: Efficacy of famciclovir in chronic hepatitis B: Results of a dose finding study, Hepatology 1996: 24:247A.
60. Benner KG, Rosen HR, Flora KD: Famciclovir treatment of decompensated cirrhosis, Hepatology 1996:24:262A.
61. Boon RJ, Saltzman R, Atkinson GF: The clinical safety experience with famciclovir, Hepatology 1996:24:282A.
62. Tillmann HL, Trautwein C, Kruger M, Bokcr K, Schlitt HJ, Condreay L, Deslauriars M, Bruns I, Pichlmayr R, Manns MP: Inhibition of hepatitis B virus replication with lamivudine in patients previously treated with famciclovir after liver transplantation, J Hepatol 1997; 26(suppl 1): 153.
63. Shaw T, Mok SS, Locarnini SA: Inhibition of hepatitis B virus DNA polymerase by enan-tiomers of penciclovirtriphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir, Hepatology 1996; 24:996-1002
64. Shaw T, Amor P, Boyd M, Locarnini S: In vitro activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus, Antimicrob Agents Chemother 1994:38:719-723.
65. llslcy DD, Lee SH, Miller WH, Kuchta RD: Acyclicguanosine analogues inhibit DNA polymerase a, 8 and e with very different potencies and have very unique mechanisms of action, Biochemistry 1995:34:2504-2510.
66. Zoulim F, Dannaoui E, Trepo C: Inhibitory effect of penciclovir on the priming of hepad-navirus reverse transcription, Abstracts of the 35th Interscicncc Conference on Antimicrobial Agents and Chemotherapy, Washington, American Society of Microbiology, 1995. p 182.
67. Lin E, Luscombe C, Wang Y, Shaw S, Locarnini S: The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B infection in vivo, Antimicrob Agents Chemother 1996:40:413-418.
68. Korba BE: In vitro evaluation of combination therapies against hepatitis B virus replication, Antiviral Res 1995:29:49-51.
69. Dcmctris AJ, Todo S, Van Thiel DH, Fung JJ, Iwaki Y, Svsyn G, Ming W, Trager J, Starzl TE: Evol ul ion of hepatitis B virus liver d iseasc after liver replacement, Practical and theoretical considerations, Am J Pathol 1990:137:667-676.
70. Davies SE, Portmann BC, O'Gradv JG, Aldis PM, Chaggar K, Alexander GJ, Williams R: Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis, Hepatology 1991:13:150-157.
71. Brook MG, Karayiannis P, Thomas HC; Which patients with chronic hepatitis B virus infection will respond to alpha-interfcron therapy? Hepatology 1989:10:761-763.
72. Twu JS, Lee CH, Lin PM, Schloemer RJ: Hepatitis B virus suppresses expression of human beta interferon, Proc Natl Acad Sci USA 1988: 85:252-256.
73. Whitten T, Qucts A, Schloemer R: Identification of the hepatitis B virus factor that inhibits expression of the beta interferon gene, J Virol 1991;65:4699-4704.
74. Onji M, Lever AM, Saito I, Thomas HC: Defective response to interferons in cells transfected w ith the hepatitis B virus genome, Hepatology 1989;9:92-96.
75. Marinos G, Naoumov NV, Williams R: Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection, Hepatology 1996:24: 991-995.
76. Jung MC, Diepolder HM, Spengler U, Wicren-ga EA, Zachoval R, Hoffmann RM, Eichcnlaub D, Frosner G, Will H, Pape GR: Activation of a heterogenous hepatitis B core and e-antigen specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection, J Virol 1995:69:3358-3368.
77. Benhamou Y, Dohin E, Fabiani FL, Poynard T, Huraux JM, Katlama C, Opolon P, Gcntilini M: Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients, Lancet 1995:11:396-397.
78. Todo S, Demetris AJ, Van Thiel D, Tcper-mann L, Fung JJ, Starzl TE: Orthotopic liver transplantation for patients with hepatitis B virus related liver disease, Hepatology 1991:13: 619-626.
79. Van Thiel D, Wright HI, Fagiuoli S: Liver transplantation for hepatitis B virus associated cirrhosis: A progress report, Hepatology 1994: 20:20S-23S.
80. Samuel D, Muller R, Alexandre G, Fassati L, Ducot B, Benhamou JP, Bismuth H and European Concerted Action on Viral Hepatitis (EU-ROHEP): Liver transplantation in 1-IBsAg positive patients: A European experience, N Engl J Med 1993:329:1842-1847.
81. Tcrrault NA, Wright TL: Hepatitis B virus infection and liver transplantation, Gut 1997; 40:568-571.
82. Grellier L, Dusheiko GM: Hepatitis B virus and liver transplantation: Concepts in antiviral prophylaxis, J Viral Hepatitis 1997:4(suupl I): 111-116.
83. Lok A, Lian R, Chiu E, Wong KL: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy, Gastroenterology 1991:100:182-188.
84. Lam K, Lai C, Trcpo C, Wu P: Deleterious effect of prednisolone in HBsAg positive chronic active hepatitis, N Engl J Med 1980: 304:380-384.
85. Tur-Kaspa R, Burk R, Shaul Y, Shafritz D: Hepatitis B virus contains a glucocorticoid-responsive element, Proc Natl Acad Sci USA 1986:82:1627-1631.
86. Muller R, Samuel D, Fassati LR, Benhamou JP, Bismuth H, Alexander GJM: ‘EUROHEP’ consensus report on the management of liver transplantation for hepatitis B virus infection, J Hepatol 1994;21:1140-1143.
87. Lauchart W, Muller R, Pichlmayr R: Longterm immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts, Transplant Proc 1987; 19:4051-4053.
88. Miiller R, Gubernatis G, Farle M, Niehoff G, Klein H, Wittekind C, Tusch G, Lautz HU, Bokcr K, Stangcl W, et al: Liver transplantation in HBsAg carriers: Prevention of hepatitis B virus recurrence by passive immunization, J Hepatol 1991;13:90-96.
89. Terrauli NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Aschcr NL, Wright TL: Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin, Hepatology 1996:24:1327-1333.
90. Carman WF, Trautwein C, van Deursen FJ, Colman C, Dornan E, McIntyre G, Waters J, Liem V, Muller R, Thomas HC, Manns MP: Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis, Hepatology 1996;24:489-493.
91. Carman WF: The clinical significance of surface antigen variants of hepatitis B virus, J Viral Hepatitis I997;4(suppl 1):11-20.
92. Bain VG, Knctemann N, Ma M, Gutfrcund KS, Shapiro JA, Fischer KP, Tipples G, Lee H, Jewell LD, Tyrrell DLJ: Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation, Transplantalion 1996;62:1456-1462.
93. Gutfreund KS, Fischer KP, Tipples G, Ma M, Knctemann N, Jewell LD, Tyrrell DLJ: Late breakthrough ofHBV viremia with lamivudine as a single agent for prevention of graft reinfection in liver transplantation for cirrhosis secondary to hepatitis B, Hepatology 1996:24: 285.
94. Markowitz J, Pakrasi A, Hollis P, Martin P, Goldstein L, Busuttii R: Efficacy of lamivudine for prophylaxis and treatment of hepatitis B in liver transplant patients, Hepatology 1996:24: 182A.
95. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzcndahl H, Con-dreav LD, Tzakis AG, Sehiff ER, Brown NA: Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation, Lancet 1997:349:20-22.
96. Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R: Beneficial effect of lamivudine in recurrent hepatitis B post liver transplantation, Hepatology 1996 ,24, 482A.
97. Perillo R, Rakela J, Martin P, Levy G, Sehiff E, Wright T, Dienstag J, Gish R, Villeneuvc J, Caldwell S, Brown N, Self P: Lamivudine transplant group: Lamivudine for hepatitis B after liver transplantation, Hepatology 1996: 24:182A.
98. Woolf GM, Wagner DA, Petrovic LM, Brown N, Ames SA, Vierling JM: Quantitative liver function testing during lamivudine therapy of fibrosing cholestatic hepatitis due to recurrent hepatitis B virus after liver transplantation, Hcpatology 1996:24:599A.
99. Tisdale M, Kemp SD, Parry NR, Larder BA: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidinc inhibitors due to a mutation in the YMDD region of reverse transcriptase, Proc Natl Acad Sci USA 1993:90:5653-5656.
100. Schinazi RF, Lloyd RM, Nguyen MIL Cannon DL, McMillan A, llksoy N, Chu CK, Liotta DC, Bazmi HZ, Mcllors JW: Characterisation of human immunodeficiency viruses resistant to oxathiolanc-cytosinc nucleosides, Antimicrob Agents Chemothcr 1993;37:875-881.
101. Mayers D: Rational approaches to resistance: Nucleoside analogues, AIDS 1996; 10(suppl I):S9-S13.
102. Ling R, Mutimer D, Ahmed M, Boxhall EH, Elias E, Dushciko GM, Harrison TJ: Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine, Hepatology 1996: 24:711-713.
103. Tipples GA, Ma MM, Fischer KP, Bain VG, Knctemann NM, Tyrell DL: Mutation in HBV RNA-depcndcnt DNA polymerase confers resistance to lamivudine in vivo, Hepatology 1996;24:714-717.
104. Tipples GA, Ma MM, Fischer KP, Bain VG, Gutfrcund KS, Knetemann NM, Tyrell DL: Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo, Hepatology 1996;24:283A.
105. De Man RA, Bartholomeusz A, Locamini S, Niestcrs HGM, Zondervan PE: The occurrence of sequential viral mutations in a liver transplant recipient reinfected with hepatitis B: Primary famciclovir resistance followed by a lethal hepatitis during acquired lamivudine resistance, J Hepatol 1997;26(suppl 1):77.
106. Tillmann HL, Trautwcin C, Bock T, Glowen-ka M, Kruger M, Boeker K, Jacckel F, Pichl-rnayr R, Condray L, Bruns I, Delaurias M, Gauther J, Manns MP: Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation, Hepatology 1997;26(suppl I):429.
107. Naoumov M, Chokshi S, Smith H, Williams R: Emergence and characterisation of lamivudine resistant hepatitis B virus variant, Hepatology 1996;24:282A.
108. Poch O, Sauvaget I, Dclaruc M, Tordo N: Identification of four conserved motifs among the RNA-dcpcndent polymerase encoding elements, EMBO J 1989:8:3867-3874.
109. Jacobo-Molina A, Ding T, Nanni RG, Clark AD, Lu X, Tantillo C, Williams RL, Kanter G, Ferris AL, Clark P, et al: Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double stranded DNA at 3.0 A resolution shows bent DNA, Proc Natl Acad Sci USA 1993:90: 6320-6324.
110. Aye TT, Bartholomeusz A, Shaw T, Bresch-kin A, Groenen L, Bowden S, McMillan J, Angus P, McCaughan GW, Locamini S: Polymerase mutations during famciclovir therapy in patients following liver transplantation, Hepatology 1996:24:285A.
111. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, Locar-nini S: Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation, J Hepatol 1997; 26:1148-1153.
112. Fischer KP, Tyrell DU: Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine in vitro, Antimicrob Agents Chemother 1996;40:1957-1960.
113. Fischer K P, Cheng YC, Tyrell DIJ: The mutation in duck hepatitis B virus polymerase which confers resistance to lamivudine also confers cross resistance to beta-/_-dideoxy-5-fluorocytidinc, Hepatology 1996:24:188A.
114. Wa nberg MA: Increased fidelity of drug selected Ml84V mutated HIV-I reverse transcriptase as the basis of effectiveness of lamivudine in HIV clinical trials, Leukemia 1997: 1 (Suppl 3):85-88.
115. Schuurtnan R, Nijhuis M, Van Lecuwen R, Schipper P, De Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, et al: Rapid in vitro selection of human immunodeficiency virus type 1 RNA load and appearance of drug-resistant populations in persons treated with lamivudine, J Infect Dis 1994: 171:1411-1419.
116. Hahn BH, Shaw GM, Taylor ME, Redfield RR, Markham PD, Salahuddin SZ, Wong-Staal F, Gallo RC, Parks ES, Parks WP: Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS, Science 1986:232:1548-1553.
117. Girones R, Miller RH: Mutation rate of the hepadnavirus genome, Virology 1989; 170: 595-597.